INSMED INC (INSM) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 543.51M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 1.16B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 2.10B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $543.51M | (m) | $1.16B | $2.10B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $542.22M | (m) | $1.22B | $2.08B | (m) |
| 2025-12-31 | (m) | (m) | (m) | $540.96M | (m) | $1.43B | $2.26B | (m) |
| 2025-09-30 | (m) | (m) | (m) | $539.72M | (m) | $1.68B | $2.36B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $538.51M | (m) | $1.86B | $2.48B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $1.11B | (m) | $1.20B | $1.80B | (m) |
| 2024-12-31 | (m) | (m) | (m) | $1.10B | (m) | $1.43B | $2.03B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $954.83M | (m) | $1.47B | $2.05B | (m) |
| 2024-06-30 | (m) | (m) | $224.45M | $946.83M | (m) | $1.25B | $1.81B | (m) |
| 2024-03-31 | (m) | (m) | $224.19M | $939.08M | (m) | $595.73M | $1.16B | (m) |
| 2023-12-31 | (m) | (m) | (m) | $1.16B | (m) | $780.45M | $1.33B | (m) |
| 2023-09-30 | (m) | (m) | (m) | $1.15B | (m) | $785.95M | $1.32B | (m) |
| 2023-06-30 | (m) | (m) | (m) | $1.14B | (m) | $917.77M | $1.44B | (m) |
| 2023-03-31 | (m) | (m) | (m) | $1.13B | (m) | $998.68M | $1.52B | (m) |
| 2022-12-31 | (m) | (m) | (m) | $1.13B | (m) | $1.15B | $1.66B | (m) |
| 2022-09-30 | (m) | (m) | (m) | $784.80M | (m) | $513.29M | $994.82M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $783.98M | (m) | $554.87M | $1.05B | (m) |
| 2022-03-31 | (m) | (m) | (m) | $783.16M | (m) | $635.12M | $1.15B | (m) |
| 2021-12-31 | (m) | (m) | (m) | $566.59M | (m) | (m) | $1.24B | (m) |
| 2021-09-30 | (m) | (m) | (m) | $557.60M | (m) | (m) | $1.31B | (m) |
| 2021-06-30 | (m) | (m) | (m) | $548.75M | (m) | (m) | $1.23B | (m) |
| 2021-03-31 | (m) | (m) | (m) | $361.57M | (m) | (m) | $692.39M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $356.32M | (m) | (m) | $796.15M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $351.13M | (m) | (m) | $840.72M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $346.00M | (m) | (m) | $885.37M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $340.94M | (m) | (m) | $676.52M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $335.94M | (m) | (m) | $742.30M | (m) |
| 2019-09-30 | (m) | (m) | (m) | $331.00M | (m) | (m) | $763.12M | (m) |
| 2019-06-30 | (m) | (m) | (m) | $326.13M | (m) | (m) | $802.78M | (m) |
| 2019-03-31 | (m) | (m) | (m) | $321.31M | (m) | (m) | $595.91M | (m) |
| 2018-12-31 | (m) | (m) | (m) | $316.56M | (m) | (m) | $604.56M | (m) |
| 2018-09-30 | (m) | (m) | (m) | $311.86M | (m) | (m) | $661.51M | (m) |
| 2018-06-30 | (m) | (m) | (m) | $307.16M | (m) | (m) | $724.24M | (m) |
| 2018-03-31 | (m) | (m) | (m) | $302.71M | (m) | (m) | $773.15M | (m) |
| 2017-12-31 | (m) | (m) | $0.00 | $55.57M | (m) | (m) | $462.05M | (m) |
| 2017-09-30 | (m) | (m) | (m) | $55.39M | (m) | (m) | $506.21M | (m) |
| 2017-06-30 | (m) | (m) | (m) | $55.19M | (m) | (m) | $165.64M | (m) |
| 2017-03-31 | (m) | (m) | (m) | $54.99M | (m) | (m) | $200.66M | (m) |
| 2016-12-31 | (m) | (m) | (m) | $54.79M | (m) | (m) | $237.96M | (m) |
| 2016-09-30 | (m) | (m) | (m) | $34.68M | (m) | (m) | $276.64M | (m) |
| 2016-06-30 | (m) | (m) | $8.69M | $16.14M | (m) | (m) | $299.68M | (m) |
| 2016-03-31 | (m) | (m) | $5.67M | $19.11M | (m) | (m) | $327.71M | (m) |
| 2015-12-31 | (m) | (m) | $3.11M | $22.03M | (m) | (m) | $356.56M | (m) |
| 2015-09-30 | (m) | (m) | $25.26M | (m) | (m) | (m) | $385.74M | (m) |
| 2015-06-30 | (m) | (m) | $25.12M | (m) | (m) | (m) | $408.51M | (m) |
| 2015-03-31 | (m) | (m) | $24.99M | (m) | (m) | (m) | $206.15M | (m) |
| 2014-12-31 | (m) | (m) | (m) | $24.86M | (m) | (m) | $230.86M | (m) |
| 2014-09-30 | (m) | (m) | $5.18M | $14.71M | (m) | (m) | $235.44M | (m) |
| 2014-06-30 | (m) | (m) | $3.28M | $16.49M | (m) | (m) | $150.11M | (m) |
| 2014-03-31 | (m) | (m) | $5.19M | $14.57M | (m) | (m) | $166.62M | (m) |
| 2013-12-31 | (m) | (m) | $3.28M | $16.34M | (m) | (m) | $176.50M | (m) |
| 2013-09-30 | (m) | (m) | $7.05M | $12.54M | (m) | (m) | $189.95M | (m) |
| 2013-06-30 | (m) | (m) | $4.65M | $14.89M | (m) | (m) | $138.72M | (m) |
| 2013-03-31 | (m) | (m) | $4.88M | $14.51M | (m) | (m) | $143.02M | (m) |
| 2012-12-31 | (m) | (m) | $3.01M | $16.22M | (m) | (m) | $153.56M | (m) |
| 2011-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $139.83M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |